NASDAQ:CALA - Calithera Biosciences Stock Price, Forecast & News

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Calithera Biosciences Inc (NASDAQ:CALA) announced its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.07. View Calithera Biosciences' Earnings History.

Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Calithera Biosciences.

3 brokerages have issued 12-month target prices for Calithera Biosciences' stock. Their forecasts range from $7.00 to $8.00. On average, they expect Calithera Biosciences' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 10.3% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.

Headlines about CALA stock have been trending very negative on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Calithera Biosciences earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Calithera Biosciences.

Some companies that are related to Calithera Biosciences include Dicerna Pharmaceuticals (DRNA), Zogenix (ZGNX), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), IGM Biosciences (IGMS), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Supernus Pharmaceuticals (SUPN), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC) and Endonovo Therapeutics (ENDV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Celadon Group (CGI), Dynavax Technologies (DVAX), First Solar (FSLR), Camtek (CAMT), Plug Power (PLUG) and Exelixis (EXEL).

Calithera Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BVF Inc. IL (17.78%), Delphi Management Partners VIII L.L.C. (4.51%), Sofinnova Investments Inc. (2.71%), Renaissance Technologies LLC (2.24%), Point72 Asset Management L.P. (1.87%) and State Street Corp (1.58%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Susan Molineaux and Value Fund L P Biotechnology. View Institutional Ownership Trends for Calithera Biosciences.

CALA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Oxford Asset Management LLP, Bank of America Corp DE, Prudential Financial Inc., Acadian Asset Management LLC, Jane Street Group LLC, Cubist Systematic Strategies LLC and Citigroup Inc.. View Insider Buying and Selling for Calithera Biosciences.

CALA stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Delphi Management Partners VIII L.L.C., Sofinnova Investments Inc., Renaissance Technologies LLC, State Street Corp, Jacobs Levy Equity Management Inc., AQR Capital Management LLC and California Public Employees Retirement System. Company insiders that have bought Calithera Biosciences stock in the last two years include Bvf Partners L P/Il, Susan Molineaux and Value Fund L P Biotechnology. View Insider Buying and Selling for Calithera Biosciences.

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CALA stock can currently be purchased for approximately $6.80.

Calithera Biosciences has a market capitalization of $365.70 million and generates $22.25 million in revenue each year. The biotechnology company earns $-54,630,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Calithera Biosciences employs 79 workers across the globe.View Additional Information About Calithera Biosciences.

The official website for Calithera Biosciences is http://www.calithera.com/.

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]